Microsoft word - pr_nbp axcan pylera july 2009 final.doc

NewBridge Pharmaceuticals Announces Licensing of Pylera® for Middle East,
Africa, Turkey & Caspian Region
Dubai and San Francisco, July 22, 2009
NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company
serving the Middle East, Africa, Turkey & Caspian regions, today announced that is has entered
into an exclusive license and supply agreement with Axcan Pharma for Pylera®, an innovative 3-
in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as
being the main cause of gastric and duodenal ulcers. Pursuant to the agreement, NewBridge is
entitled to obtain exclusive rights in certain markets where it obtains required regulatory
approvals and launches the product. The product should be launched in Q4 2010.
Pylera®, which was developed by Axcan over the last ten years, is a patented 3-in-1 capsule
therapy. Each Pylera® capsule contains bismuth subcitrate potassium, metronidazole and
tetracycline hydrochloride. Pylera® is clinically proven to be as effective as the most widely
prescribed therapeutic regimen for the eradication of Helicobacter pylori (omeprazole,
amoxicillin and clarithromycin) and has the potential to be used in a wide range of patients as a
first-line therapy for the eradication of Helicobacter pylori based on its convenient 10-day
treatment dosing regimen. Pylera® provides additional clinical benefit by improving patient
compliance. Pylera® received FDA approval in September 2006 and was successfully launched
in the United States in May 2007.
"In partnering with Axcan for the Pylera 3-in-1 capsule therapy for Helicobacter pylori
eradication, NewBridge Pharmaceuticals advances further to become one of the key providers of
innovative pharmaceutical care to the Middle East, Turkey, CIS and Africa" said Dr. Garrett
Vygantas, CEO of NewBridge Pharmaceuticals. “NewBridge’s strategy of providing world-class
sales and marketing, pharmacovigilance and supply chain support for our innovative products
allows patients and physicians across the region access to best-in-class therapeutics, education
and support.”
“We are happy to be partnering with NewBridge Pharmaceuticals,” said Nicholas Franco,
Axcan’s Senior Vice President, International Commercial Operations, “which will enable
Axcan’s Pylera to be launched in rapidly growing markets in which NewBridge has expertise.”

About Helicobacter pylori

The discovery in 1983 of the Helicobacter pylori organism was one of the major advances in
gastroenterology in recent decades, as it has revolutionized the approach to many upper
gastrointestinal disorders. Helicobacter pylori is believed to cause a spectrum of diseases in
humans, including gastritis, ulcer disease (gastric and duodenal), gastric cancer and gastric
lymphoma. In North-America, 10% of the population will have an ulcer in their lifetime; and
many treatments end up with a high rate of recurrences. In fact, 40% to 80% of patients
experience a recurrence within only a year after undergoing short-term treatment of gastric acid
suppression therapy. Studies have shown that the gastroduodenal reoccurrence rate is only 2% for
patients in whom the organism has been eradicated.

About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals ( is a specialty pharmaceutical, biologics, and
medical device company serving the Middle East, Africa, Turkey, and Caspian regions to address
the unmet needs of diseases with high regional prevalence such as cancer, diabetes, obesity,
cardiovascular diseases and other metabolic disorders. NewBridge in-licenses and
commercializes FDA and EMEA approved therapeutics, medical devices and diagnostics.
Headquartered in UAE with Business Development in the US, NewBridge was founded in 2007
by Burrill & Company, a San Francisco based Life Science Venture Capital, Private Equity,
Merchant Banking and Media firm. NewBridge Pharmaceuticals is uniquely positioned as the
partner of choice for pharmaceutical, biotechnology and device companies seeking to capture
value from their products in these high growth emerging markets.
About Axcan Pharma
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and
markets a wide range of products to treat gastrointestinal diseases and disorders, such as
inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and
complications related to pancreatic insufficiency. Axcan's products are marketed by its own
dedicated and specialized sales forces both in North America and the European Union. The
company also markets its products in more than 40 countries through a global network of local
NewBridge Pharma Media Contact:
Peter Winter
Tel: (415) 591-5474
Axcan Pharma media Contact:
Isabelle Adjahi
Senior Director, Investor Relations and Communications
Axcan Pharma
Tel: (450) 536-7696


Cough assessment questionnaire

Cough - General Advice for Patients Cough is common as part of a respiratory infection but cough going on for eight weeks or more is less common and often leads to referral for specialist help. Doctors and health professionals think of the following possibilities when a cough has developed either following an upper respiratory infection or spontaneously and continues for this time. The caus

Curr Obes RepDOI 10.1007/s13679-012-0012-0OBESITY TREATMENT (AM SHARMA, SECTION EDITOR)Attention Deficit/Hyperactivity Disorder and the ClinicalManagement of ObesitySherry Pagoto & Carol Curtin & Bradley M. Appelhans &Miguel Alonso-Alonso# Springer Science+Business Media, LLC 2012Abstract Attention deficit/hyperactivity disorder (ADHD)pharmacological treatment, exercise, and cogn

Copyright © 2010-2014 Internet pdf articles